Suppr超能文献

重组促甲状腺素和锂剂克服了胺碘酮诱导的甲状腺毒症女性低放射性碘摄取。

Recombinant TSH and Lithium Overcomes Amiodarone-Induced Low Radioiodine Uptake in a Thyrotoxic Female.

作者信息

Laplano Nestor Eric R, Mercado-Asis Leilani B

机构信息

Section of Endocrinology and Metabolism, University of Santo Tomas Hospital, Manila, Philippines.

出版信息

Int J Endocrinol Metab. 2012 Fall;10(4):625-8. doi: 10.5812/ijem.5406. Epub 2012 Sep 30.

Abstract

INTRODUCTION

Recombinant human thyroid-stimulating hormone(rhTSH) increases radioactive iodine uptake(RAIU) in selected populations, while lithium is used as an adjunct to radioactive iodine (RAI) therapy in Graves' disease with low RAIU. In this report, both drugs used in combination, overcame low iodine-131 uptake in a Graves' patient.

CLINICAL CASE

A 39-year old female with Graves' disease, acquired thionamide-induced agranulocytosis, and severe hypokalemia, subsequently went into cardiorespiratory arrest. On resuscitation, she had ventricular tachyarrhythmias which were cardioverted using amiodarone. She was subsequently placed on IV hydrocortisone amiodarone and propranolol. On admission, she was normotensive, tachycardic, and afebrile. She had fine tremors, hyper reflexia, and diffuse, non-tender thyromegaly. Initial investigations showed normal complete blood count, hypokalemia and elevated alanine transaminase levels. Levels of thyroid stimulating hormone were low (0.03 uIU/L, N = 0.27-3.75). Thyroid ultrasound showed diffuse thyromegaly with uniform echopattern and normal color flow Doppler, radioiodine uptake showed low uptake at 0400h and 2400h (6% and 7%, respectively). In preparation for RAI therapy, she was given lithium 900mg/day for 12 days to increase RAI retention. To increase iodine-131 uptake, two doses of 0.9mg rhTSH were injected intramuscular, 24 hours apart, before RAI therapy. Repeat RAIU after the second dose of rhTSH showed more than a 5-fold increase in 0400h uptake compared with the baseline (32% vs. 6%). Exactly 24 hours after the second dose of rhTSH, she was given 25mCi of iodine-131. Thereafter, the patient's clinical and biochemical markers continued to improve. She became hypothyroid and is currently on levothyroxine replacement therapy.

CONCLUSIONS

This case demonstrates the efficacy of combining rhTSH and lithium to overcome amiodarone-induced low iodine-131 uptake in Graves' disease.

摘要

引言

重组人促甲状腺激素(rhTSH)可增加特定人群的放射性碘摄取(RAIU),而锂在放射性碘摄取低的格雷夫斯病中用作放射性碘(RAI)治疗的辅助药物。在本报告中,两种药物联合使用,克服了一名格雷夫斯病患者的低碘-131摄取。

临床病例

一名39岁患有格雷夫斯病、获得性硫代酰胺诱导的粒细胞缺乏症和严重低钾血症的女性,随后发生心肺骤停。复苏时,她出现室性快速心律失常,使用胺碘酮进行了复律。随后她接受了静脉注射氢化可的松、胺碘酮和普萘洛尔治疗。入院时,她血压正常、心动过速且无发热。她有细微震颤、反射亢进,甲状腺弥漫性肿大且无压痛。初始检查显示全血细胞计数正常、低钾血症和丙氨酸转氨酶水平升高。促甲状腺激素水平低(0.03 uIU/L,正常范围为0.27 - 3.75)。甲状腺超声显示甲状腺弥漫性肿大,回声均匀,彩色多普勒血流正常,放射性碘摄取显示在04:00和24:00时摄取低(分别为6%和7%)。为准备放射性碘治疗,她服用锂900mg/天,共12天以增加放射性碘潴留。为增加碘-131摄取,在放射性碘治疗前24小时,分两次间隔24小时肌肉注射0.9mg rhTSH。第二次注射rhTSH后的重复放射性碘摄取显示,04:00时的摄取量与基线相比增加了5倍多(32%对6%)。在第二次注射rhTSH exactly 24小时后,她接受了25mCi的碘-131。此后,患者的临床和生化指标持续改善。她出现了甲状腺功能减退,目前正在接受左甲状腺素替代治疗。

结论

本病例证明了联合使用rhTSH和锂可克服胺碘酮诱导的格雷夫斯病患者低碘-131摄取的疗效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验